The FDA today outlined its plans for finalizing guidance on its Breakthrough Device Program as well as plans for a new Safer Technologies Program (STeP) intended to encourage device tech that significantly improves safety as compared to current devices on the market.
The FDA said last week that its preliminary review of long-term follow-up data found a “potentially concerning signal” of increased long-term mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices compared to those treated with bare devices.
The FDA today floated some ideas on how it might regulate medical devices armed with artificial intelligence - also known as software-as-a-medical-device (SaMD) - whose algorithms can change based on machine learning (ML) and possibly affect people in ways for which they were not approved or cleared.
Whether you are a first-time inventor or a large manufacturer, the thrill of bringing a medical device to market is both exhilarating and overwhelming. The development of a successful device not only requires optimized design efforts, but also clinical, regulatory & marketing expertise. Download this 30 min. webinar and increase your chances of successfully launching your medical device.
Most members of the FDA’s Medical Devices Advisory Committee panel on neurological devices said age should not be a consideration for inclusion in a clinical trial, but life expectancy should, and patients with less than one year of life expectancy should be excluded from studies.
The FDA proposes a rule that would amend regulations regarding the classification of products as biological products, devices, drugs or combination products.
genae was interviewed by Pharma Tech Outlook on the complexities of clinical trials. Discover this must-read article and how genae identified an unmet need for excellence in medical device clinical trials.
The FDA said today it has begun more closely scrutinizing the roles of certain materials associated with harm to patients who have breast implants, nitinol-containing devices, metal-on-metal hip implants and devices made from animal-derived substances.
A panel of experts convened by the FDA yesterday said that there’s not enough data to pull textured breast implants from the market over concerns that they may be linked to a type of immune system cancer, according to an AP News report.